Enox Biopharma, Inc. Grants Ortho Dental Solutions LTD License for the Treatment of Periodontal Disease

VANCOUVER, British Columbia, Jan. 5, 2011 /PRNewswire/ -- Enox Biopharma, Inc. (VANCOUVER, B.C.), a leader in the development of innovative solutions for infections associated with medical devices, and Ortho Dental Solutions LTD (Tel Aviv, Israel) today announced an execution of an exclusive royalty bearing license agreement under which Enox Biopharma shall grant Ortho Dental Solutions LTD rights to patent application and knowhow for use in developing novel therapies limited in use for dental and gum diseases.

Under this agreement, ODS will use Enox Biopharma technologies to develop an innovative treatment for Periodontal disease. Enox formulation has been proven as an effective agent against a wide range of bacterial infections and ODS will use the formulation to develop novel products in order to reduce post dental treatment infections and to prevent periodontal disease.

Periodontal disease remains one of the most common diseases throughout the world which, if left untreated, can lead to tooth loss. Periodontal disease is a chronic bacterial infection that affects the gums and bone supporting the teeth. Periodontal disease can affect one tooth or many teeth. Periodontal disease is associated with biofilm and its formation that causes the gums to become inflamed and infected.

Prof. David Greenberg, M.D., Enox Biopharma Chief Medical Officer, stated, "We are very pleased with this agreement which valued our technology and further develops our franchise in dental diseases that affect millions of patients worldwide. Periodontal diseases, and Gingivitis in particular, is a serious public health problem that requires effective and well tolerated treatment in order to significantly decrease the prevalence of the disease."

Prof. Herbert Judes, M.D., Ortho Dental Solutions Chief Executive Officer, stated, "Periodontal diseases is today one of the most common diseases in the world. Forty percent of the population suffers from dental disease, the main cause of which is potential pathogens that are found in our mouths. A large part of the population will lose their teeth due to these infections. We believe that by using the Enox formulation we can develop better solutions for conservative treatment and control of periodontal disease."  

About Ortho Dental Solutions LTD  

Ortho Dental Solutions LTD (Tel Aviv, Israel) is a privately held company focusing on clinical development and commercialization of innovative products for the dentistry and oral health industry.

About Enox Biopharma, Inc.

Enox Biopharma, Inc. is an emerging biotechnology company with proprietary technology that embeds nitric oxide (NO) into polymeric medical devices. The innate immune system uses NO to block microbial growth – embedding NO into medical devices makes them antimicrobial. Enox's technology is applicable to any indwelling polymeric medical device including, but not limited to, catheters, endotracheal tubes, tympanostomy tubes and cosmetic implants. With the current CMS non-coverage of nosocomial infections the financial burden of infections has shifted to hospitals who are desperately seeking ways to reduce infection rates. By utilizing NO, part of the human body's innate immune system, Enox Biopharma is improving existing medical devices by making them uniquely antimicrobial. Reducing infection rates without antibiotics benefits patients, physicians, hospitals and decreases the overall cost of health care.

Forward Looking Information

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on management's good faith views and expectations when made. Forward-looking statements are inherently subject to known and unknown risks and uncertainties which, in the case of the company, include raising adequate capital to continue operations, technology and product development uncertainties, and competition. Actual financial results of the company may differ, perhaps materially, from those discussed in the forward-looking statements. The company is not obligated, and does not undertake, to update its forward-looking statements or comment on the differences that may develop between its statements and actual results. Readers are encouraged to refer to the recent public filings of the company to further ascertain the risks associated with the forward-looking statements. Readers are urged not to place undue reliance upon such statements.

SOURCE Enox Biopharma, Inc.